MXC takes first steps into pharmaceutical world
Published 03-MAR-2016 09:46 A.M.
|
2 minute read
Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.
In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.
The below articles were written under our previous business model. We have kept these articles online here for your reference.
Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.
Click Here to View Latest Articles
MGC Pharma (ASX:MXC) has taken the first steps into the world pharmaceuticals, developing an R&D agreement with an Israeli company to develop technology which can deliver pharmaceuticals directly to the brain.
It told its shareholders today that it had entered a collaboration agreement with SipNose, which has been hard at work developing the SipNose device.
The device, pictured below, promises to bypass the ‘blood brain barrier’ to deliver pharmaceuticals directly to the brain – leading to more effective treatment.
Normally drugs need to be absorbed into the bloodstream of a patient before making their way to the effective areas.
It opens up a new treatment option for diseases such as Alzheimer’s, Parkinson’s, and epilepsy.
MXC and SipNose are focusing on epilepsy, using a pharmaceutical product derived from medical cannabis in the form of cannabinoid compounds to help in the treatment of the disease.
According to Cure Epilepsy, 65 million people worldwide suffer some form of the disease.
The pair will enter into R&D, basing the research out of the Hadassah Medical Centre in Israel.
Should the R&D come off, MXC will investigate taking an exclusive global license for the SipNose device to be used to relieve epilepsy with a medical cannabis-based treatment.
Managing director of MGC Pharma Nativ Segev said that the deal with SipNose was a signal that it was about to become a fully-fledged pharmaceutical player.
“This partnership represents our first step towards establishing MXC’s medical R&D operations,” he said. “Our partnership with SipNose also signals our commitment to becoming a leading medical cannabis pharmaceuticals company and accelerates our path to market.”
From cosmetics to pharma
MXC, a recent listing on the ASX following the recent completion of a reverse takeover of Erin Resources has thus far focused on the cosmetic rather than the pharmaceutical game.
It launched an initial range of 15 CBD based cosmetic products this year under its MGC DERMA brand – although it has flagged intentions to deliver a total of 50 CBD based cosmetic products in the first half of this year.
These include facial creams, eye serums, soaps, toners, and cleansing milks with compounds derived from medical cannabis.
It is thought, however, that the main game for MXC has been to get into the pharmaceutical market – and it has in the past sold ‘active pharmaceutical ingredients’ derived from cannabis to other pharmaceutical companies.
The move into R&D though effectively signals its market entry into the fully-fledged pharmaceutical market.
General Information Only
S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.
Conflicts of Interest Notice
S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.
Publication Notice and Disclaimer
The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.
Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.
This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.
